- Biopharma News
ProBioGen selected for development and large-scale manufacturing services24 Mar 2020
The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.
Immunogenesis — a spin-off of the MD Anderson Cancer Center, University of Texas — has selected ProBioGen for cell line development, process development and GMP manufacturing in 1,000-L bioreactor scale for their lead Immuno-Oncology candidate.
The lead candidate is a first-in-class monoclonal antibody with two different specificities resulted from R&D work at the MD Anderson Cancer Center, University of Texas.
Using its CHO.RiGHT expression platform for high-titer cell line development, ProBioGen will support the development and conduct large-scale manufacturing of Immunogenesis’ promising molecule in ProBioGen’s new facility.
Now, with two facilities in Berlin, ProBioGen is prepared to accommodate the increased demand for manufacturing.
Michael A. Curran, founder of Immunogenesis and associate professor at the MD Anderson Cancer Center, said: “With ProBioGen we found the right partner that has great scientific expertise and the ‘can-do’ mindset which we very much appreciate for this challenging step.”
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation